Antibody-drug conjugates in prostate cancer: current landscape and future directions - PubMed
5 hours ago
- #Prostate Cancer
- #Targeted Therapy
- #Antibody-Drug Conjugates
- ADCs combine monoclonal antibodies with cytotoxic payloads for targeted cancer therapy.
- Key targets in prostate cancer include PSMA, TROP-2, and B7-H3, with multiple ADCs in trials.
- Newer ADCs show improved tolerability and efficacy over early versions hindered by toxicity.
- Combinations with hormonal, targeted, and immune-based therapies are being explored to enhance outcomes.
- ADCs offer promise for metastatic castration-resistant prostate cancer where treatment options are limited.